Preimplantation genetic testing for hereditary angioedema as a potential dominant cost-effective intervention

Willem Roosens; Lore Lannoo; Ellen Denayer; Liesbeth Gilissen; Karen Peeraer; Eftychia Dimitriadou; Jeroen Luyten; Kristel Van Calsteren; Rik Schrijvers

doi:10.1016/j.jaip.2024.12.023

Preimplantation genetic testing for hereditary angioedema as a potential dominant cost-effective intervention

J Allergy Clin Immunol Pract. 2024 Dec 24:S2213-2198(24)01267-4. doi: 10.1016/j.jaip.2024.12.023. Online ahead of print.

Authors

Willem Roosens¹, Lore Lannoo², Ellen Denayer³, Liesbeth Gilissen¹, Karen Peeraer², Eftychia Dimitriadou³, Jeroen Luyten⁴, Kristel Van Calsteren², Rik Schrijvers⁵

Affiliations

¹ Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.
² Department of Obstetrics and Gynaecology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
³ Centre for Human Genetics, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
⁴ Department of Public Health and Primary Care, Faculty of Medicine, KU Leuven, Leuven, Belgium.
⁵ Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium. Electronic address: [email protected].

PMID: 39725317
DOI: 10.1016/j.jaip.2024.12.023

No abstract available

Keywords: C1 inhibitor; angioedema; assisted reproductive technology; budget impact analysis; hereditary angioedema; pregnancy counseling; preimplantation genetic testing.